Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML

Pediatr Int. 2020 Jun;62(6):742-744. doi: 10.1111/ped.14172. Epub 2020 Jun 4.

Authors

Naoki Kajita¹, Yuya Saito¹, Atsushi Makimoto², Satoshi Miyahara³, Yuki Yuza¹

Affiliations

¹ Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.
² Division of Pathology and Laboratory Medicine, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.
³ Division of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

PMID: 32495974
DOI: 10.1111/ped.14172

No abstract available

Keywords: cyclophosphamide; double recurrence; etoposide; rhabdomyosarcoma; s-AML.

Publication types

Case Reports

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Etoposide / adverse effects
Etoposide / therapeutic use
Fatal Outcome
Humans
Ifosfamide / therapeutic use
Japan
Leukemia, Myeloid, Acute / chemically induced*
Leukemia, Myeloid, Acute / drug therapy
Male
Neoplasm Recurrence, Local*
Neoplasms, Second Primary / chemically induced*
Neoplasms, Second Primary / drug therapy
Rhabdomyosarcoma, Alveolar / drug therapy*

Substances

Etoposide
Cyclophosphamide
Ifosfamide